BioVie, Inc. Common Stock
BIVIBioVie, Inc. is a biotech company focused on developing innovative therapies for neurodegenerative and liver diseases. The company is known for its research into drug candidates aimed at addressing unmet medical needs, particularly in conditions such as hepatic encephalopathy. BioVie's approach involves leveraging novel mechanisms and proprietary formulations to create impactful treatments.
Company News
BioVie Inc. will host an investor webinar on December 9, 2025, featuring CEO Cuong Do discussing their drug candidates bezisterim and BIV201 for neurological diseases and liver cirrhosis, highlighting clinical progress and potential market opportunities.
BioVie Inc. will host an investor webinar discussing its drug therapies for neurological diseases, focusing on bezisterim for Alzheimer's, Parkinson's, and long COVID, and BIV201 for liver cirrhosis complications.
BioVie Inc. has priced a public offering of 6 million units at $2.00 per unit, expecting to raise approximately $12 million. The offering includes common stock and warrants, with proceeds intended for working capital and general corporate purposes.
BioVie Inc. is pricing a public offering of 6 million units, each consisting of one common stock share and one warrant, expected to raise approximately $12 million for working capital and general corporate purposes.
BioVie presented research showing its drug Bezisterim potentially reduces biological age in Alzheimer's patients by modulating DNA methylation across multiple biological clocks, with significant improvements in inflammatory and metabolic biomarkers.
